Bigul

Supriya Lifescience Ltd - 543434 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompaySupriya Lifescience Ltd 2CINL51900MH2008PLC180452 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY A- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Shweta Singh Designation: Company Secretary and Compliance Officer EmailId: cs@supriyalifescience.com Name of the Chief Financial Officer: Ashish Nayak Designation: Chief financial Officer EmailId: cfo@supriyalifescience.com Date: 30/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
30-04-2022
Bigul

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Pursuant to the relevant provisions of the SEBI Listing Regulations, we would like to inform you that the officials of our Company, Supriya Lifescience Limited ('Company') will be interacting with Analysts/Investors on April 28, 2022. This is to further inform that the copy of the Investor Presentation has been uploaded on the Stock Exchanges and on the Company's website www.supriyalifescience.com for your information and for the information of your members and the public at large. This information is submitted to you pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015. Note: The above date is subject to change. Change may happen due to exigencies on the part of Company or Analyst/Investor/Fund. Request you to kindly take the same on record.
28-04-2022
Bigul

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Pursuant to the relevant provisions of the SEBI Listing Regulations, we would like to inform you that the officials of our Company, Supriya Lifescience Limited ('Company') will be interacting with Analysts/Investors on April 25, 2022 via video conference. This is to further inform that the copy of the Investor Presentation which was referred during the meeting has been already uploaded on the website of the Company www.supriyalifescience.com and is also available on the Stock Exchanges for the public at large. No unpublished price sensitive information (UPSI) was discussed during the interactions. Request you to kindly take the same on record.
25-04-2022
Bigul

Supriya Lifescience Ltd - 543434 - Submission Of Certificate Required Under Regulation 40(10) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

With reference to the subject captioned above, please find enclosed herewith the certificate under Regulation 40(9) of the SEBI [Listing Obligations and Disclosure Requirements] (LODR) Regulations, 2015 for the year ended March 31, 2022 required to be submitted to the stock exchange as per the Regulation 40(10) of the SEBI (LODR) Regulations, 2015. Kindly take the same on your record and acknowledge the receipt.
12-04-2022
Bigul

Supriya Lifescience Ltd - 543434 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompaySupriya Lifescience Ltd 2CINL51900MH2008PLC180452 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY A- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Shweta Singh Designation: Company Secretary and Compliance Officer EmailId: cs@supriyalifescience.com Name of the Chief Financial Officer: Ashish Nayak Designation: Chief financial Officer EmailId: cfo@supriyalifescience.com Date: 12/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
12-04-2022
Bigul

Supriya Lifescience Ltd - 543434 - Compliance Certificate Pursuant To Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Year Ended 31St March, 2022

Please find enclosed herewith Compliance Certificate issued in terms of Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the financial year ended on March 31, 2022 duly signed by authorized representative of Link Intime India Private Limited (Registrar and Transfer Agent of the Company) and the Compliance Officer of the Company, certifying compliance with the requirements of Regulation 7(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Request you to kindly take the same on record.
11-04-2022
Bigul

Supriya Lifescience Ltd - 543434 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Please find enclosed herewith a duly signed Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 received from Link Intime India Private Limited, Registrar and Share Transfer Agent of the Company for the quarter ended March 31, 2022. You are requested to kindly take the same on record.
08-04-2022
Bigul

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we would like to inform you that the officials of the Company will be organizing plant visit for Analysts at Lote, Maharashtra on April 6, 2022 and April 7, 2022. This is to further inform that the copy of the Investor Presentation has been uploaded on the Stock Exchanges and on the website of the Company www.supriyalifescience.com for your information and for the information of your members and the public at large. Note: The above date is subject to change. Change may happen due to exigencies on the part of Company or Analyst/Investor/Fund. Request you to kindly take the same on record.
05-04-2022
Bigul

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Pursuant to the relevant provisions of the SEBI Listing Regulations, we would like to inform you that the officials of our Company, Supriya Lifescience Limited ('Company') will be interacting with Analysts/Investors on April 1, 2022 via video conference. This is to further inform that the copy of the Investor Presentation which was referred during the meeting has been already uploaded on the website of the Company www.supriyalifescience.com and is also available on the Stock Exchanges for the public at large. No unpublished price sensitive information (UPSI) was discussed during the interactions. Request you to kindly take the same on record.
01-04-2022
Bigul

Supriya Lifescience Ltd - 543434 - Closure of Trading Window

In accordance with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and the Company's Code of Conduct to Regulate, Monitor and Report Trading in Securities by Insiders (hereinafter referred to as the "Prohibition of Insider Trading Code"), the Trading window for dealing in the Securities of the Company for all the Insiders, Designated Persons ((including their immediate relatives), as defined in the Code, shall remain closed from April 01, 2022 till the expiry of 48 hours after the declaration of the Audited Financial Results of the Company for the quarter and year ended March 31, 2022. The date of the Board Meeting for consideration and approval of the Audited Financial results for the quarter and year ended March 31, 2022, shall be intimated separately in due course. Kindly take the above said information on your records.
30-03-2022
Next Page
Close

Let's Open Free Demat Account